Newsroom

  • Category

  • By Date

  • Press Release

    04 July 25

    CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar

    Read more
  • Press Release

    26 April 25

    CuraTeQ Biologics receives CHMP positive opinion for Dazublys – Trastuzumab biosimilar

    Read more
  • Press Release

    10 April 25

    CuraTeQ Biologics successfully completes Phase I study for Denosumab biosimilar

    Read more
Overview
CuraTeQ Biologics

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust your preferences below.

Essential Cookies

Essential Cookies should be enabled at all times so that we can save your preferences for cookie settings. If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Google Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance